These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17072822)

  • 1. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.
    Daimon T; Goto M
    Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of the theory of the optimal sampling scheme for bioequivalence studies].
    Tod M; Petitjean O; Nicolas P
    Therapie; 1993; 48(1):7-13. PubMed ID: 8356559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic measures, their estimation and selection of sampling times.
    Fedorov V; Leonov S
    J Biopharm Stat; 2007; 17(5):919-41. PubMed ID: 17885874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal design of pharmacokinetic studies.
    Aarons L; Ogungbenro K
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):250-5. PubMed ID: 20102362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
    Bos AM; Boom K; Vinks AA; Boezen HM; Wanders J; Dombernovsky P; Aamdal S; de Vries EG; Uges DR
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):64-70. PubMed ID: 15069581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal sampling in retrospective logistic regression via two-stage method.
    Chien CY; Ivan Chang YC; Hsueh HM
    Biom J; 2011 Feb; 53(1):5-18. PubMed ID: 21259305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient estimation of log-normal means with application to pharmacokinetic data.
    Shen H; Brown LD; Zhi H
    Stat Med; 2006 Sep; 25(17):3023-38. PubMed ID: 16345103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation.
    Wajima T; Yano Y; Oguma T
    J Pharm Pharmacol; 2002 Jul; 54(7):929-34. PubMed ID: 12162711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
    Retout S; Mentré F; Bruno R
    Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.
    Dokoumetzidis A; Aarons L
    J Biopharm Stat; 2007; 17(5):851-67. PubMed ID: 17885870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimum experimental designs for properties of a compartmental model.
    Atkinson AC; Chaloner K; Herzberg AM; Juritz J
    Biometrics; 1993 Jun; 49(2):325-37. PubMed ID: 8369370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two design optimality criteria applied to a nonlinear model.
    Bogacka B; Wright F
    J Biopharm Stat; 2004 Nov; 14(4):909-30. PubMed ID: 15587972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
    Plard C; Bressolle F; Fakhoury M; Zhang D; Yacouben K; Rieutord A; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies.
    Duffull SB; Graham G; Mengersen K; Eccleston J
    J Biopharm Stat; 2012; 22(1):16-29. PubMed ID: 22204524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.